In prostate cancer, there is considerable evidence that tumors promote immune tolerance starting early in the disease. By suppressing tumors and activating immune system homeostatic mechanisms, chemotherapy may help overcome this tumor-induced immune tolerance. As such, chemotherapy may therefore support improved results from novel immune-modulating therapies. Prostate cancer is particularly suited for active immunotherapy because prostate tumor cells express a number of distinctive surface antigens. Sipuleucel-T, which has recently been approved in the United States, is an active immunotherapy that triggers T-cell responses against prostate cancer. An exploratory analysis of phase III trial participants found a substantial survival benefit to receiving docetaxel some months after sipuleucel-T. However, VITAL-2, a phase III trial investigating a prostate cancer therapeutic vaccine plus concurrent docetaxel versus standard docetaxel therapy in advanced prostate cancer, observed lower overall survival with the vaccine regimen. This trial highlights major unresolved questions concerning the optimum choice, dosing, and timing of chemotherapy relative to active immunotherapy. Patient characteristics, prostate cancer disease stage, and treatment history also may influence the response to combined therapy. Advances in biomarker validation and trial design are needed to efficiently investigate these issues.

2010-03-01·IDrugs : the investigational drugs journal

BioPartnering North America--Programs from Pharma in Europe and the Middle East.

作者: Croydon, Léonie

The BioPartnering North America conference, held in Vancouver, included presentations covering drug pipeline developments from both large and small pharmaceutical companies. This conference report highlights selected presentations from drug developers from Europe and the Middle East, specifically France, Spain, Denmark, Ireland, Sweden, Switzerland, Germany and Israel. Investigational drugs discussed include naproxcinod and NCX-116 (both NicOx SA), beta-amyloid (Abeta)40- and Abeta42-targeting vaccines (Araclon Biotech SI), ROSE-010 (Rose Pharma A/S), ADC-1004 (Alligator Bioscience AB), and VPM-4-001 (Vakzine Projekt Management GmbH).

100 项与 VPM-4001 相关的药物交易

登录后查看更多信息